Peripheral Cytopenia: A Review Of Clinical Spectrum And Management Approaches

  • Patel sunita
Keywords: Anaemia, Leucocytopenia, Nanomedicines, Peripheral cytopenia, Pharmacotherapy

Abstract

This review study thoroughly examined the causes, mechanisms, symptoms, diagnosis, and therapy options for peripheral cytopenia, namely anemia, leukopenia, and thrombocytopenia. The report outlined the several underlying factors that contribute to cytopenia, including dietary deficits, autoimmune illnesses, and bone marrow problems. The paper explored the range of symptoms and the level of severity that may occur based on the exact kind of blood cell lineage impacted and the underlying cause of cytopenia. Diagnostic techniques such as complete blood count and peripheral blood smear examination are emphasized, along with treatment strategies including pharmacotherapy, blood transfusions, and stem cell transplantation. Moreover, the study explored the developing topic of nanomedicine in the treatment of cytopenias, with a specific emphasis on the advancement of iron nanoparticles for anemia, targeted drug delivery systems for neutropenia, and platelet-coated nanoparticles for managing thrombocytopenia. In summary, this review offers a thorough analysis of peripheral cytopenia and highlights the transformative potential of nanomedicine in reshaping its therapy options.

 

Author Biography

Patel sunita

Tolani Institute of Pharmacy,Adipur-kutch, Gujarat,India,

References

1. A.S. Gupta, Bio-inspired nanomedicine strategies for artificial blood components, Wiley Interdiscipl. Rev. Nanomed. Nanobiotechnol. 9 (2017), https://doi.org/ 10.1002/wnan.1464.
2. X. Na, H. Shanfeng, Z. Yang, S. Zonghong, Roles of immune responses in the pathogenesis of immuno related pancytopenia, Scand. J. Immunol. 92 (2020) 12911, https://doi.org/10.1111/sji.12911.
3. Shukla, N. Dasgupta, S. Ranjan, S. Singh, R. Chdambaram, Nanotechnology towards prevention of anaemia and osteoporosis: from concept to market, Biotechnol. Biotechnol. Equip. 31 (2020) 863–879, https://doi.org/10.1080/ 13102818.2017.1335615.
4. S.M. Bagwe, P.P. Kale, L.K. Bhatt, K.S. Prabhavalkar, Herbal approach in the treatment of pancytopenia, J. Compl. Integr. Med. 14 (2017), https://doi.org/ 10.1515/jcim-2016-0053.
5. Hepburn AL, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology. 2010 Dec 1;49(12):2243-54.
6. Niroula K. PREVALENCE OF ANEMIA AND ASSOCIATED FACTORS AMONG NON-PREGNANT WOMEN OF REPRODUCTIVE AGE (15-49 YEARS) IN DHIMAL COMMUNITY OF DAMAK MUNICIPALITY (Doctoral dissertation).
7. Sing CW, Tang CT, Chui CS, Fan M, Lai FT, Li X, Wan EY, Wong CK, Chan EW, Hung IF, Leung AY. COVID‐19 vaccines and risks of hematological abnormalities: nested case–control and self‐controlled case series study. American Journal of Hematology. 2022 Apr;97(4):470-80.
8. Keerthy Aberna A. Role of Platelet Indices in Differentiating the Causes of Thrombocytopenia in a Tertiary Care Hospital (Doctoral dissertation, Madras Medical College, Chennai).
9. Kovalyova О, Pasiieshvili L, Frolova Т, Andrusha A, Shapkin V, Ivanchenko S. Syndromes and diseases of the blood system: textbook.
10. Gangat N, Wolanskyj AP. Anemia of chronic disease. Semin Hematol (2013) 50:232–8. doi: 10.1053/j.seminhematol.2013.06.006
11. M.D. Cappellini, I. Motta, Anemia in clinical practice-definition and classification: does hemoglobin change with aging? Semin. Hematol. 52 (4) (2015) 261–269.
12. Fattizzo B, Barcellini W. Autoimmune hemolytic anemia: causes and consequences. Expert Review of Clinical Immunology. 2022 Jul 3;18(7):731-45.
13. Biswajit H, Pratim PP, Kumar ST, Shilpi S, Krishna GB, Aditi A. Aplastic anemia: a common hematological abnormality among peripheral pancytopenia. North American journal of medical sciences. 2012 Sep;4(9):384.
14. Riley LK, Rupert J. Evaluation of patients with leukocytosis. American family physician. 2015 Dec 1;92(11):1004-11.
15. Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. InSeminars in hematology 2013 Jul 1 (Vol. 50, No. 3, pp. 198-206). WB Saunders.
16. Lv Y. Causes of peripheral blood cytopenias in patients with liver cirrhosis portal hypertension and clinical significances. Open Journal of Endocrine and Metabolic Diseases. 2014 Apr 15;2014.
17. Gleich GJ, Klion AD, Lee JJ, Weller P. The consequences of not having eosinophils. Allergy. 2013 Jul;68(7):829-35.
18. Smock KJ, Perkins SL. Thrombocytopenia: an update. International journal of laboratory hematology. 2014 Jun;36(3):269-78.
19. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004 Oct 15;104(8):2263-8.
20. Naik RP, Smith-Whitley K, Hassell KL, Umeh NI, De Montalembert M, Sahota P, Haywood Jr C, Jenkins J, Lloyd-Puryear MA, Joiner CH, Bonham VL. Clinical outcomes associated with sickle cell trait: a systematic review. Annals of Internal Medicine. 2018 Nov 6;169(9):619-27.
21. Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology 2013, the American Society of Hematology Education Program Book. 2013 Dec 6;2013(1):76-81.
22. Olcay L, Yetgin S, Aoshima H. Disorders mimicking myelodysplastic syndrome and difficulties in its diagnosis. London, UK:: IntechOpen; 2016 Sep 7.
23. Bento L, Canaro M, Bastida JM, Sampol A. Thrombocytopenia and therapeutic strategies after allogeneic hematopoietic stem cell transplantation. Journal of Clinical Medicine. 2022 Mar 2;11(5):1364.
24. Balduini CL, Pecci A, Noris P. Diagnosis and management of inherited thrombocytopenias. InSeminars in thrombosis and hemostasis 2013 Mar (Vol. 39, No. 02, pp. 161-171). Thieme Medical Publishers.
25. Massaro F, Andreozzi F, Vandevoorde C, Bron D. Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life. Cancers. 2023 Nov 13;15(22):5381.
26. Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nature reviews Clinical oncology. 2016 Apr;13(4):209-27.
27. Izak M, Bussel JB. Management of thrombocytopenia. F1000prime reports. 2014;6.
28. Stevens GA, Paciorek CJ, Flores-Urrutia MC, Borghi E, Namaste S, Wirth JP, Suchdev PS, Ezzati M, Rohner F, Flaxman SR, Rogers LM. National, regional, and global estimates of anaemia by severity in women and children for 2000–19: a pooled analysis of population-representative data. Lancet Global Health. 2022 May 1;10(5):e627-39.
29. Parasher A, Saini V, Saini A, Barik RR, Aggarwal A, Khan J. A study of the association of leukopenia with disease severity and mortality in patients diagnosed with COVID-19. International Journal of Advances in Medicine. 2020 Nov;7(11):1721.
30. Schlappi C, Kulkarni V, Palabindela P, Bemrich-Stolz C, Howard T, Hilliard L, Lebensburger J. Outcomes in mild to moderate isolated thrombocytopenia. Pediatrics. 2018 Jul 1;142(1).
31. Rivera AK, Latorre AA, Nakamura K, Seino K. Using complete blood count parameters in the diagnosis of iron deficiency and iron deficiency anemia in Filipino women. Journal of Rural Medicine. 2023;18(2):79-86.
32. KT N, Prasad K, Singh BM. Analysis of red blood cells from peripheral blood smear images for anemia detection: a methodological review. Medical & biological engineering & computing. 2022 Sep;60(9):2445-62.
33. Frelinger III AL, Grace RF, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, Neufeld EJ, Michelson AD. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood, The Journal of the American Society of Hematology. 2015 Aug 13;126(7):873-9.
34. R. Karwasra, S. Faithi, K. Raza, S. Singh, K. Khanna, S. Sharma, N. Sharma, S. Varma, Filgrastim loading in PLGA and SLN nanoparticulate system: a bioinformatics approach, Drug Dev. Ind. Pharm. 46 (2020) 1354–1361, https:// doi.org/10.1080/03639045.2020.1788071.
35. J. Hoggatt, T.A. Tate, L.M. Pelus, Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia, Int. J. Nanomed. 10 (2015) 2647–2652, https://doi.org/10.2147/IJN.S55796.
36. Matzdorff, O. Meyer, H. Ostermann, V. Kiefel, W. Eberl, T. kuhne, I. Pabinger, M. Rummel, Immune thrombocytopenia - current diagnostics and therapy: recommendations of a joint working group of DGHO, OGHO, SGH, GPOH, and DGTI, Onclol. Ress. Treat. 41 (2018) 1–30, https://doi.org/10.1159/000492187.
37. K.J. Smock, S.L. Perkins, Thrombocytopenia: an update, Int. J. Lab Hematol. 36 (2014) 269–278, https://doi.org/10.1111/ijlh.12214.
38. M.F. Aslam, D.M. Frazer, N. Faria N, S.F. Bruggraber, S.J. Wilkins, C. Mirciov, J. J. Powell, G.J. Anderson, D.A. Pereira, Ferroportin mediates the intestinal absorption of iron from a nanoparticulate ferritin core mimetic in mice, Faseb. J. 28 (2014) 3671–3678, https://doi.org/10.1096/fj.14-251520.
39. C.L. Ventola, Progress in nanomedicine: approved and investigational nanodrugs, P T 42 (2017) 742–755. https://pubmed.ncbi.nlm.nih.gov/29234213/.
40. B.S. Barot, P.B. Parejiya, D.M. Mehta, P.K. Shelat, G.B. Shah, Physicochemical and structural characterization of iron–sucrose formulations: a comparative study, Pharmaceut. Dev. Technol. 19 (2014) 513–520, https://doi.org/10.3109/ 10837450.2013.795171.
41. T. Di Francesco, G. Borchard, A robust and easily reproducible protocol for the determination of size and size distribution of iron sucrose using dynamic light scattering, J. Pharmaceut. Biomed. Anal. 152 (2018) 89–93, https://doi.org/ 10.1016/j.jpba.2018.01.029.
42. A.C. Anselmo, S. Mitragotri, Nanoparticles in the clinic, Bioeng Transl. Med. 1 (2016) 10–29, https://doi.org/10.1002/btm2.10003.
43. E.H. Shafie, S.A. Keshavarz, M.E. Kefayati, F. Taheri, P. Sarbakhsh, M. Reza Vafa, The effects of nanoparticles containing iron on blood and inflammatory markers in comparison to ferrous sulfate in anemic rats, Int. J. Prev. Med. 7 (2016) 117, https://doi.org/10.4103/2008-7802.193092.
44. K. Wang, L. Li, X. Xu, L. Lu, J. Wang, S. Wang, Y. Wang, Z. Zin, Y. Ziang, Fe3O4@ Astragalus plysaccharide core-shell nanoparticles for iron deficiency anemia therapy and magnetic resonance imaging in vivo, ACS Appl. Mater. Interfaces 11 (2019) 10452–10461, https://doi.org/10.1021/acsami.8b18648.
45. V. Garc´es, A. Rodríguez-Nogales, A. Gonz´ alez A, et al., Bacteria-carried iron oxide nanoparticles for treatment of anemia, Bioconjugate Chem. 29 (2018) 1785–1791, https://doi.org/10.1021/acs.bioconjchem.8b00245.
46. T.A. Salaheldin, In-vivo nutritional and toxicological evaluation of nano iron fortified biscuits as food supplement for iron deficient anemia, J. Nano Res. 3 (2016), 00049, https://doi.org/10.15406/jnmr.2016.03.00049.
47. M.B.M. Mohamed, S.H.A. Helmy, WO2014135170- Novel Formula of Iron Based Nanocomposite for Rapid and Efficient Treatment of Iron Deficiency Anemia, European patent, 2013. EP2964205A1.
48. F.-Y. Su, E.-Y. Chuang, P.-Y. Lin, et al., Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles, Biomaterials 35 (2014) 3641–3649, https://doi. org/10.1016/j.biomaterials.2014.01.020.
49. D.D. Von Hoff, M.M. Mita, R.K. Ramanathan, et al., Phase I Study of PSMAtargeted docetaxel containing nanoparticle BIND-014 in patients with advanced solid tumors, Clin. Canc. Res. 22 (2016) 3157–3163, https://doi.org/10.1158/ 1078-0432.CCR-15-2548.
50. A.M. Gonzalez-Angulo, F. Meric-Bernstam, S. Chawla, et al., Weekly nabRapamycin in patients with advanced nonhematologic malignancies: results of a phase I trial, Clin. Canc. Res. 19 (2013) 5474–5484, https://doi.org/ 10.1158/1078-0432.CCR-12-3110.
51. G.J. Weiss, J. Chao, J.D. Neidhart, et al., First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies, Invest. N. Drugs 31 (2013) 986–1000, https://doi.org/10.1007/s10637-012-9921-8.
52. N. Kommineni, S. Mahira, A.J. Domb, W. Khan, Cabazitaxel loaded nanocarriers for cancer therapy with reduced side effects, Pharmaceutics 11 (2019) 141, https://doi.org/10.3390/pharmaceutics11030141.
53. S. O’Brien, G. Schiller, J. Lister, et al., High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult philadelphia chromosomenegative acute lymphoblastic leukemia, J. Clin. Oncol. 31 (2013) 676–683, https://doi.org/10.1200/JCO.2012.46.2309
54. C. Mamot, R. Ritschard, A. Wicki, et al., Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study, Lancet Oncol. 13 (2012) 1234–1241, https://doi.org/10.1016/S1470-2045(12)70476-X.
55. V. Subbiah, J.E. Grilley-Olson, A.J. Combest, et al., Phase Ib/II trial of NC-6004 (Nanoparticle Cisplatin) plus gemcitabine in patients with advanced solid tumors, Clin. Canc. Res. 24 (2018) 43–51, https://doi.org/10.1158/1078-0432.CCR-17- 1114.
56. R.D.N. Arifa, T.P. Paula, M.F.M. Madeira, et al., The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan, Pharmacol. Res. 107 (2016) 102–110, https://doi.org/ 10.1016/j.phrs.2016.03.004.
57. S.K. Williamson, G.A. Johnson, H.A. Maulhardt, et al., A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies, Canc. Chemother. Pharmacol. 75 (2015) 1075–1087, https://doi. org/10.1007/s00280-015-2737-4.
58. R.K. Singh, S. Pankaj, S. Kumar, V. Rajkota, A retrospective study of efficacy and safety of albumin bound paclitaxel in metastatic breast cancer, World J. Oncol. 5 (2014) 204–209, https://doi.org/10.14740/wjon865w.
59. D. Leroux, N. Hezard, A. Lebreton, et al., Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert® HIT) for the diagnosis of heparin-induced thrombocytopenia, Br. J. Haematol. 166 (2014) 774–782, https://doi.org/10.1111/bjh.12939.
60. X. Wei, J. Gao, R.H. Fang, B.T. Luk, A.V. Kroll, D. Dehaini, J. Zhou, H.W. Kim, W. Gao, W. Lu, L. Zhang, Nanoparticles camouflaged in platelet membrane coating as an antibody decoy for the treatment of immune thrombocytopenia, Biomaterials 111 (2016) 116–123, https://doi.org/10.1016/j. biomaterials.2016.10.003.
61. V. Vijayan, S. Uthaman, I.K. Park, Cell membrane camouflaged nanoparticles: a promising biomimetic strategy for cancer theragnostics, Polymers 10 (2018) 983, https://doi.org/10.3390/polym10090983.
62. T. Tagami, T. Ozeki, Recent trends in clinical trials related to carrier-based drugs, J. Pharmacol. Sci. 106 (2017) 2219–2226, https://doi.org/10.1016/j. xphs.2017.02.026.
Published
2024-09-12
How to Cite
Patel sunita. (2024). Peripheral Cytopenia: A Review Of Clinical Spectrum And Management Approaches. Revista Electronica De Veterinaria, 25(1), 1241 - 1249. https://doi.org/10.69980/redvet.v25i1.877
Section
Articles